Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 790-795, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-922148
ABSTRACT
Small cell lung cancer (SCLC) is a neuroendocrine tumor with fast progression, high malignancy, easy recurrence, and extremely poor prognosis. In the past 30 years, the clinical treatment strategy of SCLC has been mainly chemotherapy and radiotherapy, but the curative effect is not significant; the current immunotherapy of SCLC has gradually entered the clinic and has made certain progress. Tumor immunotherapy includes immune checkpoint inhibitors, tumor vaccines, cytokines, chimeric antigen receptor T-cell immunotherapy (CAR-T) therapy, etc. Currently, immune checkpoint inhibitors are the most widely used. This article summarizes the principles of immune checkpoint inhibitors and related drugs, summarizes their domestic and foreign clinical trials progress in SCLC treatment, reviews the biomarkers used in the therapy, and discusses its future development direction.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Clinical Trials as Topic
/
Cancer Vaccines
/
Small Cell Lung Carcinoma
/
Immune Checkpoint Inhibitors
/
Immunotherapy
/
Lung Neoplasms
Type of study:
Controlled clinical trial
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS